The MassCPR is committed to moving promising therapies for COVID-19 toward clinical development and expanding our understanding of the most effective interventions to treat the disease.  To this end, our intention is to rapidly publish both negative and positive data from screening, highlighting the best potential mechanisms for development of future COVID-19 therapies. The potency and raw data derived from testing of candidate molecules will be provided to the applicant at no cost. 

The decision to proceed with, or set a priority for testing will be set by review of the rationale for testing. 

Please contact MassCPR_screening@hms.harvard.edu with questions. FAQs are below which include links to both the downloadable MTA and a set of instructions for submitting compounds for screening.